Scienture Holdings, Inc. (SCNX) News
Follow Scienture Holdings, Inc. (SCNX) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 12 public stories across 7 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
H
Why Vicor Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
Shares of Vicor Corp (NASDAQ: VICR ) rose sharply in pre-market trading after the company raised its third-quarter sequential revenue growth guidance. Vicor raised its third-quarter sequential revenue growth guidance to
LIVE | Oct 01, 2026, 08:31 AM UTC
M
Scienture says REZENOPY to be available in ~2,000 US clinics
Scienture Holdings says REZENOPY will be available in about 2,000 OTP clinics and addiction centers in the US.
EQUITY | Sep 22, 2026, 01:05 PM UTC
M
Scenture inks exclusive deal to distribute Rezennopy naloxone
Scenture Holdings (SCNX) entered an exclusive sales, marketing and distribution agreement to offer REZENOPY naloxone 10 mg via a partner network of about 2,000 U.S. OTP and addiction treatment centers.
EQUITY | Sep 22, 2026, 12:22 PM UTC
L
SCNX: Two new therapies launched in 2026 drive revenue growth and pipeline momentum
The session highlighted a data-driven approach to specialty pharma, with two new commercial products launched in 2026 and a robust pipeline targeting large markets. Revenue and market access are expanding, supported by s
NEWS | Sep 14, 2026, 08:48 PM UTC
L
SCNX: Two new therapies launched in 2026 drive revenue growth and pipeline expansion
The company leverages data-driven strategies to commercialize improved therapies, launching two products in 2026 and building a robust pipeline targeting large markets. Revenue is growing steadily, supported by strong co
NEWS | Sep 14, 2026, 08:34 PM UTC
L
Scienture posts revised investor presentation, will present to analysts and investors
Scienture posted a revised investor presentation and will present it to analysts, investors and other parties.Key Highlights:Original SEC Filing: Scienture Holdings, Inc. [ SCNX ] - 8-K - Sep. 14, 2026This is an AI-power
REGULATION | Sep 14, 2026, 08:13 PM UTC
L
SCNX: Rapid revenue growth and FDA-approved launches highlight a strong specialty pharma pipeline
Focused on innovative specialty pharmaceuticals, the company has launched FDA-approved Arbli™ and Rezenopy®, with a robust pipeline targeting CNS, cardiovascular, and pain markets. Strong IP, experienced leadership, and
REGULATION | Sep 14, 2026, 08:02 PM UTC
L
Scienture to present at H.C. Wainwright global investment conference Sept. 14, 2026
Scienture said management will highlight commercial momentum of Arbli™ and the commercial launch of REZENOPY™ at the H.C. Wainwright 28th Annual Global Investment Conference on Sept. 14, 2026.
EQUITY | Sep 09, 2026, 01:01 PM UTC
L
SCIENTURE to present at H.C. Wainwright conference on Sept. 14
SCIENTURE will present at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026.
EQUITY | Sep 09, 2026, 12:55 PM UTC
L
SCIENTURE (SCNX) reports Q2 2026 results with ~510% sequential revenue growth
SCIEnTURE (SCNX) reports Q2 2026 results, citing approximately 510% sequential revenue growth from Q1 2026 and a significant improvement in operating performance.
EARNINGS | Aug 14, 2026, 12:08 PM UTC
M
SCNX Launches REZENOPY Nasal Spray
SCNX fulfills initial purchase orders of REZENOPY, the highest dose FDA-approved naloxone nasal spray
EQUITY | Aug 12, 2026, 12:05 PM UTC
H
Why WD-40 Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket
Shares of WD-40 Co (NASDAQ: WDFC ) rose sharply in pre-market trading after the company reported better-than-expected third-quarter financial results. The company reported quarterly earnings of $2.33 per share, which bea
RATES | Jul 10, 2026, 08:45 AM UTC